Tradestie Institutional Equity Comparison Engine

BMED vs CRBN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRBN Overall Edge

CRBN Captures Institutional Edge (1โ€“1 Pillars ยท 2โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to iShares MSCI ACWI Low Carbon Target ETF (CRBN) driven by superior Options & Structure while BMED counters with relative strength in Momentum & Technical. Fundamentally, BMED trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CRBN at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, BMED sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against CRBN sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BMED N/M vs CRBN N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner BMED
1Y +26.3% vs +7.7% ยท 52W Pos 86% vs 67%
Options & Structure Winner CRBN
UNCLASSIFIED (100th %ile IV) vs UNCLASSIFIED (50th %ile IV)
BMED NYSE Arca
iShares Health Innovation Active ETF
Institutional Equity
$35.93
-1.06% 1D
Market Cap N/A
1M Return +3.99%
1Y Return +26.28%
Forward P/E N/M
Unified AI Score
51.8 / 100 HOLD
Tech 44.0 Fund 44.0 Flow 50.0 Mom 41.6
CRBN NYSE Arca
iShares MSCI ACWI Low Carbon Target ETF
Institutional Equity
$246.75
-1.94% 1D
Market Cap N/A
1M Return -2.73%
1Y Return +7.74%
Forward P/E N/M
Unified AI Score
60.1 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BMED +26.28% CRBN +7.74% Spread: +15.93 pp (BMED Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BMED TTM Op. Margin: N/A CRBN TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMED vs CRBN. Trailing 12-month operating profitability (BMED N/A vs CRBN N/A) and valuation multiples (BMED N/M vs CRBN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BMED (1) vs CRBN (2)
Institutional Metric BMED CRBN Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 86% ($27โ€“$37) 67% ($215โ€“$262) Stronger Trend BMED
Beta / 30D Volatility Risk Regime 0.61ฮฒ ยท 24% Vol 1.07ฮฒ ยท 22% Vol Lower Realized Risk CRBN
Unified Institutional Score Composite Signal 51.8 / 100 (HOLD) 60.1 / 100 (BUY) Higher Composite CRBN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BMED vs CRBN Buy Guide
BMED UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live BMED Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRBN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRBN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BMED nor CRBN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.